Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis

Majid Ghareghani, Linda Scavo, Yahya Jand, Naser Farhadi, Hossein Sadeghi, Amir Ghanbari, Stefania Mondello, Damien Arnoult, Sajjad Gharaghani, Kazem Zibara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Metabolic disturbances have been implicated in demyelinating diseases including multiple sclerosis (MS). Melatonin, a naturally occurring hormone, has emerged as a potent neuroprotective candidate to reduce myelin loss and improve MS outcomes. In this study, we evaluated the effect of melatonin, at both physiological and pharmacological doses, on oligodendrocytes metabolism in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Results showed that melatonin decreased neurological disability scores and enhanced remyelination, significantly increasing myelin protein levels including MBP, MOG, and MOBP. In addition, melatonin attenuated inflammation by reducing pro-inflammatory cytokines (IL-1β and TNF-α) and increasing anti-inflammatory cytokines (IL-4 and IL-10). Moreover, melatonin significantly increased brain concentrations of lactate, N-acetylaspartate (NAA), and 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR). Pyruvate dehydrogenase kinase-4 (PDK-4) mRNA and protein expression levels were also increased in melatonin-treated, compared to untreated EAE mice. However, melatonin significantly inhibited active and total pyruvate dehydrogenase complex (PDC), an enzyme under the control of PDK4. In summary, although PDC activity was reduced by melatonin, it caused a reduction in inflammatory mediators while stimulating oligodendrogenesis, suggesting that oligodendrocytes are forced to use an alternative pathway to synthesize fatty acids for remyelination. We propose that combining melatonin and PDK inhibitors may provide greater benefits for MS patients than the use of melatonin therapy alone.

Original languageEnglish
Article number147
JournalFrontiers in Pharmacology
Volume10
Issue numberFEB
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Melatonin
Multiple Sclerosis
Pyruvate Dehydrogenase Complex
Therapeutics
Autoimmune Experimental Encephalomyelitis
Oligodendroglia
Cytokines
Myelin Proteins
Demyelinating Diseases
Myelin Sheath
Interleukin-1
Interleukin-4
Interleukin-10
Lactic Acid
Oxidoreductases
Anti-Inflammatory Agents
Fatty Acids
Hormones
Pharmacology
Inflammation

Keywords

  • Melatonin
  • Multiple sclerosis
  • Myelin
  • Pyruvate dehydrogenase complex
  • Pyruvate dehydrogenase kinase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. / Ghareghani, Majid; Scavo, Linda; Jand, Yahya; Farhadi, Naser; Sadeghi, Hossein; Ghanbari, Amir; Mondello, Stefania; Arnoult, Damien; Gharaghani, Sajjad; Zibara, Kazem.

In: Frontiers in Pharmacology, Vol. 10, No. FEB, 147, 01.01.2019.

Research output: Contribution to journalArticle

Ghareghani, M, Scavo, L, Jand, Y, Farhadi, N, Sadeghi, H, Ghanbari, A, Mondello, S, Arnoult, D, Gharaghani, S & Zibara, K 2019, 'Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis', Frontiers in Pharmacology, vol. 10, no. FEB, 147. https://doi.org/10.3389/fphar.2019.00147
Ghareghani, Majid ; Scavo, Linda ; Jand, Yahya ; Farhadi, Naser ; Sadeghi, Hossein ; Ghanbari, Amir ; Mondello, Stefania ; Arnoult, Damien ; Gharaghani, Sajjad ; Zibara, Kazem. / Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. FEB.
@article{26d3ae4c0007473f9643138968d91e57,
title = "Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis",
abstract = "Metabolic disturbances have been implicated in demyelinating diseases including multiple sclerosis (MS). Melatonin, a naturally occurring hormone, has emerged as a potent neuroprotective candidate to reduce myelin loss and improve MS outcomes. In this study, we evaluated the effect of melatonin, at both physiological and pharmacological doses, on oligodendrocytes metabolism in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Results showed that melatonin decreased neurological disability scores and enhanced remyelination, significantly increasing myelin protein levels including MBP, MOG, and MOBP. In addition, melatonin attenuated inflammation by reducing pro-inflammatory cytokines (IL-1β and TNF-α) and increasing anti-inflammatory cytokines (IL-4 and IL-10). Moreover, melatonin significantly increased brain concentrations of lactate, N-acetylaspartate (NAA), and 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR). Pyruvate dehydrogenase kinase-4 (PDK-4) mRNA and protein expression levels were also increased in melatonin-treated, compared to untreated EAE mice. However, melatonin significantly inhibited active and total pyruvate dehydrogenase complex (PDC), an enzyme under the control of PDK4. In summary, although PDC activity was reduced by melatonin, it caused a reduction in inflammatory mediators while stimulating oligodendrogenesis, suggesting that oligodendrocytes are forced to use an alternative pathway to synthesize fatty acids for remyelination. We propose that combining melatonin and PDK inhibitors may provide greater benefits for MS patients than the use of melatonin therapy alone.",
keywords = "Melatonin, Multiple sclerosis, Myelin, Pyruvate dehydrogenase complex, Pyruvate dehydrogenase kinase",
author = "Majid Ghareghani and Linda Scavo and Yahya Jand and Naser Farhadi and Hossein Sadeghi and Amir Ghanbari and Stefania Mondello and Damien Arnoult and Sajjad Gharaghani and Kazem Zibara",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00147",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "FEB",

}

TY - JOUR

T1 - Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis

AU - Ghareghani, Majid

AU - Scavo, Linda

AU - Jand, Yahya

AU - Farhadi, Naser

AU - Sadeghi, Hossein

AU - Ghanbari, Amir

AU - Mondello, Stefania

AU - Arnoult, Damien

AU - Gharaghani, Sajjad

AU - Zibara, Kazem

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Metabolic disturbances have been implicated in demyelinating diseases including multiple sclerosis (MS). Melatonin, a naturally occurring hormone, has emerged as a potent neuroprotective candidate to reduce myelin loss and improve MS outcomes. In this study, we evaluated the effect of melatonin, at both physiological and pharmacological doses, on oligodendrocytes metabolism in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Results showed that melatonin decreased neurological disability scores and enhanced remyelination, significantly increasing myelin protein levels including MBP, MOG, and MOBP. In addition, melatonin attenuated inflammation by reducing pro-inflammatory cytokines (IL-1β and TNF-α) and increasing anti-inflammatory cytokines (IL-4 and IL-10). Moreover, melatonin significantly increased brain concentrations of lactate, N-acetylaspartate (NAA), and 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR). Pyruvate dehydrogenase kinase-4 (PDK-4) mRNA and protein expression levels were also increased in melatonin-treated, compared to untreated EAE mice. However, melatonin significantly inhibited active and total pyruvate dehydrogenase complex (PDC), an enzyme under the control of PDK4. In summary, although PDC activity was reduced by melatonin, it caused a reduction in inflammatory mediators while stimulating oligodendrogenesis, suggesting that oligodendrocytes are forced to use an alternative pathway to synthesize fatty acids for remyelination. We propose that combining melatonin and PDK inhibitors may provide greater benefits for MS patients than the use of melatonin therapy alone.

AB - Metabolic disturbances have been implicated in demyelinating diseases including multiple sclerosis (MS). Melatonin, a naturally occurring hormone, has emerged as a potent neuroprotective candidate to reduce myelin loss and improve MS outcomes. In this study, we evaluated the effect of melatonin, at both physiological and pharmacological doses, on oligodendrocytes metabolism in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Results showed that melatonin decreased neurological disability scores and enhanced remyelination, significantly increasing myelin protein levels including MBP, MOG, and MOBP. In addition, melatonin attenuated inflammation by reducing pro-inflammatory cytokines (IL-1β and TNF-α) and increasing anti-inflammatory cytokines (IL-4 and IL-10). Moreover, melatonin significantly increased brain concentrations of lactate, N-acetylaspartate (NAA), and 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR). Pyruvate dehydrogenase kinase-4 (PDK-4) mRNA and protein expression levels were also increased in melatonin-treated, compared to untreated EAE mice. However, melatonin significantly inhibited active and total pyruvate dehydrogenase complex (PDC), an enzyme under the control of PDK4. In summary, although PDC activity was reduced by melatonin, it caused a reduction in inflammatory mediators while stimulating oligodendrogenesis, suggesting that oligodendrocytes are forced to use an alternative pathway to synthesize fatty acids for remyelination. We propose that combining melatonin and PDK inhibitors may provide greater benefits for MS patients than the use of melatonin therapy alone.

KW - Melatonin

KW - Multiple sclerosis

KW - Myelin

KW - Pyruvate dehydrogenase complex

KW - Pyruvate dehydrogenase kinase

UR - http://www.scopus.com/inward/record.url?scp=85065833869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065833869&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00147

DO - 10.3389/fphar.2019.00147

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - FEB

M1 - 147

ER -